argenex (NASDAQ:ARGX) Stock Rating Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of argenex (NASDAQ:ARGX) from a buy rating to a hold rating in a research note issued to investors on Sunday morning,Wall Street Zen reports.

Other research analysts also recently issued reports about the company. Guggenheim lowered their target price on argenex from $1,185.00 to $1,120.00 and set a “buy” rating on the stock in a research note on Friday. Morgan Stanley increased their price target on argenex from $1,140.00 to $1,190.00 and gave the stock an “overweight” rating in a report on Friday. Wedbush lowered their price objective on shares of argenex from $1,150.00 to $1,130.00 and set an “outperform” rating on the stock in a research report on Thursday, October 8th. Citizens Jmp boosted their price objective on shares of argenex from $932.00 to $1,200.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 18th. Finally, Wells Fargo & Company cut their price objective on shares of argenex from $1,356.00 to $1,336.00 and set an “overweight” rating for the company in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,142.37.

argenex Stock Performance

Shares of ARGX opened at $873.71 on Friday. argenex has a fifty-two week low of $661.85 and a fifty-two week high of $1,072.75. The firm has a 50-day simple moving average of $956.62 and a 200-day simple moving average of $886.34. The company has a market capitalization of $54.95 billion, a price-to-earnings ratio of 30.49, a price-to-earnings-growth ratio of 0.89 and a beta of 0.44.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Friday, October 23rd. The company reported $7.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $7.44 by $0.36. The firm had revenue of $1.75 billion for the quarter. argenex had a return on equity of 47.70% and a net margin of 31.66%. Equities research analysts forecast that argenex will post 25.79 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ARGX. Janus Henderson Group PLC lifted its holdings in argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock valued at $1,847,592,000 after acquiring an additional 83,568 shares during the period. Jennison Associates LLC increased its holdings in shares of argenex by 3.4% in the 1st quarter. Jennison Associates LLC now owns 237,468 shares of the company’s stock valued at $173,411,000 after purchasing an additional 7,707 shares in the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of argenex by 1.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 175,311 shares of the company’s stock valued at $130,277,000 after purchasing an additional 2,579 shares in the last quarter. First Trust Advisors LP lifted its stake in shares of argenex by 98.9% in the first quarter. First Trust Advisors LP now owns 107,195 shares of the company’s stock valued at $78,279,000 after purchasing an additional 53,293 shares during the period. Finally, Eagle Health Investments LP lifted its stake in shares of argenex by 21.7% in the first quarter. Eagle Health Investments LP now owns 76,336 shares of the company’s stock valued at $55,744,000 after purchasing an additional 13,606 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex News Summary

Here are the key news stories impacting argenex this week:

• Positive Sentiment: Strong quarterly results: argenx reported $7.80 in EPS, exceeding the $7.44 consensus estimate, while revenue reached $1.75 billion. Product net sales grew 54% year over year to $1.7 billion, and operating profit was $486 million. argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Bullish analyst support: Morgan Stanley raised its price target from $1,140 to $1,190 and maintained an “overweight” rating. Wells Fargo also maintained “overweight” despite trimming its target from $1,356 to $1,336. Jefferies called the post-news setup a potentially attractive entry point. Morgan Stanley rating
• Neutral Sentiment: Targets remain above the market price, but revisions are mixed: Guggenheim lowered its target from $1,185 to $1,120 while keeping a “buy” rating. Robert W. Baird raised its target from $823 to $861 but retained a “neutral” rating, and RBC reportedly cut its target. These changes suggest continued confidence in long-term value but more cautious near-term expectations. Guggenheim rating
• Negative Sentiment: Clinical-development setback is overshadowing the earnings beat: Reports highlighted a surprise testing setback for argenx’s core drug, raising concerns about future growth, product expansion and execution. That issue appears to be driving the weaker investor reaction despite the company’s strong sales and profitability. argenx testing setback

argenex Company Profile

argenx SE (NASDAQ: ARGX) is a global immunology company focused on developing and commercializing therapies for patients with severe autoimmune diseases. The company uses its antibody engineering capabilities to discover and advance medicines designed to target disease-causing immune mechanisms.

argenx’s lead product is VYVGART (efgartigimod alfa), an antibody fragment that targets the neonatal Fc receptor, or FcRn, to reduce levels of disease-causing immunoglobulin G antibodies. VYVGART is approved in several markets for the treatment of generalized myasthenia gravis.